330 related articles for article (PubMed ID: 27106404)
1. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
[TBL] [Abstract][Full Text] [Related]
2. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
[TBL] [Abstract][Full Text] [Related]
5. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.
Hänscheid H; Sweeney RA; Flentje M; Buck AK; Löhr M; Samnick S; Kreissl M; Verburg FA
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1284-8. PubMed ID: 22526964
[TBL] [Abstract][Full Text] [Related]
6. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
Bartolomei M; Bodei L; De Cicco C; Grana CM; Cremonesi M; Botteri E; Baio SM; Aricò D; Sansovini M; Paganelli G
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1407-16. PubMed ID: 19319527
[TBL] [Abstract][Full Text] [Related]
8. Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy.
Backhaus P; Huss S; Kösek V; Weckesser M; Rahbar K
Clin Nucl Med; 2018 Jun; 43(6):e184-e185. PubMed ID: 29688946
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
10. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
11. Will
Braat AJAT; Snijders TJ; Seute T; Vonken EPA
Cardiovasc Intervent Radiol; 2019 Nov; 42(11):1649-1652. PubMed ID: 31187231
[TBL] [Abstract][Full Text] [Related]
12. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Receptor Theranostics for Refractory Meningiomas.
Salgues B; Graillon T; Horowitz T; Chinot O; Padovani L; Taïeb D; Guedj E
Curr Oncol; 2022 Aug; 29(8):5550-5565. PubMed ID: 36005176
[TBL] [Abstract][Full Text] [Related]
14. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
[TBL] [Abstract][Full Text] [Related]
15. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
Puranik AD; Dev ID; Rangarajan V; Kulkarni S; Shetty N; Gala K; Sahu A; Bhattacharya K; Dasgupta A; Chatterjee A; Gupta T; Sridhar E; Sahay A; Shetty P; Singh V; Moiyadi A; Menon N; Purandare NC; Agrawal A; Shah S; Choudhury S; Ghosh S; Jha AK
Neurol India; 2024 Mar; 72(2):278-284. PubMed ID: 38691470
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
18. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U
J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of peptide receptor radionuclide therapy with [
Minczeles NS; Bos EM; de Leeuw RC; Kros JM; Konijnenberg MW; Bromberg JEC; de Herder WW; Dirven CMF; Hofland J; Brabander T
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1195-1204. PubMed ID: 36454268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
